{"nctId":"NCT03257813","briefTitle":"Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)","startDateStruct":{"date":"2016-04-01","type":"ACTUAL"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"count":60,"armGroups":[{"label":"Group A","type":"OTHER","interventionNames":["Drug: PRO-122","Drug: Krytantek Ofteno®"]},{"label":"Group B","type":"OTHER","interventionNames":["Drug: PRO-122","Drug: Krytantek Ofteno®"]}],"interventions":[{"name":"PRO-122","otherNames":["timolol, dorzolamide, brimonidine"]},{"name":"Krytantek Ofteno®","otherNames":["timolol, dorzolamide, brimonidine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years of age or older\n* male or female.\n* obtained in the external consultation.\n* With diagnosis primary of open-angle glaucoma and / or hypertension classified as mild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least two months prior to inclusion and under control of the target IOP.\n* informed consent.\n\nExclusion Criteria:\n\nGeneral Criteria\n\n1. Subjects with topical or systemic medication that interferes decisively in the results of the study. (Such as topical immunomodulators, lacrimal point tamponade, corticosteroids, ocular hypotensives other than those listed above, artificial tears with preservative).\n2. Subjects (female) with an active sex life who are not using a contraceptive method.\n3. Female Subjects in pregnancy or breastfeeding.\n4. Female subjects with positive urine pregnancy test.\n5. Positive drug addiction (verbal interrogation).\n6. Subjects who have participated in any clinical research study in the last 40 days.\n7. Legally or mentally disabled subjects to give informed consent for their participation in this study.\n8. Subjects who can not comply with the appointments or with all the requirements of the protocol.\n\nOphthalmologic criteria\n\n1. Subject with only one eye with vision.\n2. Subjects with visual capacity 20/200 or worse.\n3. Subjects with a narrow-angle history without treatment, with or without total or partial closure of the angle in either eye.\n4. Subjects with corneal abnormalities that prevent applanation tonometry.\n5. Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.\n6. Any ocular laser surgery 3 months prior.\n7. Any uncontrolled or progressive retinal disease.\n8. Inflammatory diseases of any kind.\n9. Contact lens wearers.\n10. Subjects with a history of hypersensitivity to any of the ingredients of the research product or its analogues.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressure (IOP)","description":"Intraocular pressure, Unit: Millimeters of mercury (mmHg) type of variable: Continuous, Measurement method: Goldman applanation tonometry. Normal intraocular pressure 11-21 mmHg.\n\nThe change between the IOP of both groups was compared (sequence 1 versus sequence 2) of the data obtained at the end of each period (day 30 and day 60).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.60","spread":"2.9"},{"groupId":"OG001","value":"12.13","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.19","spread":"3.2"},{"groupId":"OG001","value":"11.80","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.60","spread":"3.0"},{"groupId":"OG001","value":"11.24","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Visual Acuity (VA)","description":"The VA will be evaluated basally, without refractive correction with the Snellen chart. A Snellen chart is placed at a standard distance: 20 ft. At this distance, the symbols on the line representing \"normal\" acuity subtend. This line, designated 20/20 is the smallest line that a person with normal acuity can read at a distance of 20fs. the scale consists of 11 lines of letters of different size, the size of the letter gives a fractional value according to the visual acuity of the patient, the value is inversely proportional to the visual acuity, if the denominator is greater the visual acuity will be less.\n\nLine 1: 20/200 Line 2: 20/100, Line 3: 20/70, line 4: 20/50, line 5: 20/40, Line 6: 20/30, line 7: 20/25, Line 8: 20/20, line 9: 20/15, line 10: 20/13, line 11: 20/10. the differences between groups in the basal, cross over and final visit will be evaluated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.31","spread":"3.577"},{"groupId":"OG001","value":"39.48","spread":"3.742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.85","spread":"3.806"},{"groupId":"OG001","value":"40.43","spread":"3.753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.98","spread":"3.717"},{"groupId":"OG001","value":"35.50","spread":"3.402"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events","description":"The presence of adverse events by percentage between groups will be evaluated. the scale is present or absent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Conjunctival Hyperemia","description":"the conjunctival hyperemia will be evaluated by the presence or absence of it and the percentage of affected by group will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Chemosis","description":"Chemosis: qualitative ordinal variable, will be evaluated by the presence or absence of it and the percentage of affected by group will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Eye Burning","description":"Eye ocular burning will be evaluated by the presence or absence of it and the number of affected by group will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Eyes With Tearing","description":"Tearing will be evaluated by the presence or absence of it and the number of affected by group will be reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Eyes With Foreign Body Sensation","description":"Foreign body sensation will be evaluated by the presence or absence of it and the number of affected by group will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["rhinopharyngitis","pharyngitis tonsillitis","Dotted Keratopathy","headache","allergic Blepharokeratoconjunctivitis"]}}}